丹红注射液对肺心病患者心肺功能与血液流变学影响的Meta分析  

Meta analysis of the effects of Danhong injection on the cardiopulmonary function and blood theological characters of pulmonary heart disease

作　　者：金梅 王瑜[1] 臧宝霞[2] JIN Mei;WANG Yu;ZANG Baoxia(School of Statistics,Renmin University of China,Beijing 100872,China)

机构地区：[1]中国人民大学统计学院,100782 [2]首都医科大学附属北京安贞医院-北京市心肺血管疾病研究所

出　　处：《心肺血管病杂志》2021年第1期85-92,共8页Journal of Cardiovascular and Pulmonary Diseases

摘　　要：目的:评价丹红注射液改善肺源性心脏病(肺心病)患者心肺功能和血液流变学的临床疗效。方法:检索Pubmed、medline、EMbase、Cochrane Library Datebase、CNKI、VIP、WanFang Data,收集丹红注射液治疗肺心病的临床随机对照试验(RCTs),检索时限均为建库至2020年1月19日,采用Cochrane风险评价表评价各研究质量,State 15.0软件合并统计量并进行敏感性检验,以begg法和egger法进行发表偏倚分析。结果:共纳入21篇RCTs文献,累计2151例患者。Meta分析结果显示,丹红注射液+常规治疗组和常规治疗组相比可显著提高患者总有效率(OR=4.15,95%CI:3.17~5.43),丹红注射液还可提高肺心病患者心脏射血分数(EF),提高患者FEV1,降低肺动脉压(PAP),降低全血高切黏度和全血低切粘度,提高PaO_(2)并降低PaCO_(2),两组比较各项指标(P均<0.001)。和常规治疗组相比,丹红注射液的不良反应发生率未见明显升高。结论:和常规治疗相比,丹红注射液+常规治疗可显著提高肺心病的临床疗效,且可明显增强患者的心肺功能,降低肺动脉压,改善血液流变学,且安全性良好。Objective:To evaluate the clinical efficacy of Danhong injection in improving cardiopulmonary function and blood fuidity in patients with pulmonary heart disease by Meta analysis.Methods:Pubmed,medline,EMbase,Cochrane Library English Database and CNKI,VIP,WanFang Chinese Database were searched,and the papers of clinical randomized controlled trials(RCTs)of Danhong injection in the treatment of pulmonary heart disease were collected.The duration of search time was from the day of database establishment to January 19,2020.The quality of every studies were assessed according to the Cochrane risk scale.Various statistical analysises including statistical quantities combination,homogeneity assessment,sensitivity analysis,beg test and egger test were performed with State 15.0 software.Results:In our analysis a total of 21 RCTs literatures were included,with a total of 2151 patients.Meta-analysis result showed that Danhong injection+conventional treatment group(DC group)can significantly improve the total effective rate compared with conventional treatment group(C group)with(OR=4.15,95%CI:3.17-5.43)in patients with pulmonary heart disease.In these patients Danhong injection can improve cardiac ejection fraction,increase the patient’s 1 st second forced expiratory volume,reduce pulmonary artery pressure,reduce whole blood high shear viscosity and whole blood low shear viscosity,increase PaO_(2) and reduce PaCO_(2),differences of the data of every parameter between above two groups were statistical significant(P all<0.001).Compared with the C group,the incidence of adverse reactions in DC group did not increase significantly.Conclusions:Compared with conventional treatment,Danhong injection+conventional treatment can significantly improve the clinical efficacy of pulmonary heart disease,and can significantly enhance the patient’s cardiopulmonary function,reduce pulmonary artery pressure,improve blood fluidity,and its safety is good.

关 键 词：丹红注射液 肺源性心脏病 随机对照试验 META分析 

分 类 号：R54[医药卫生—心血管疾病]